Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody

Abstract Fifteen patients with refractory Hodgkin's disease were treated in a dose-escalation trial with the bispecific monoclonal antibody (bi-mAb) HRS-3/A9, which is directed against the Fcγ receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen. Treatment consisted of four cycles ... Ausführliche Beschreibung

1. Person: Renner, Christoph
Weitere Personen: Hartmann, Frank; Jung, Wolfram; Deisting, Christina; Juwana, Marieta; Pfreundschuh, Michael
Quelle: in Cancer immunology immunotherapy : CII Vol. 49 (2000), p. 173-180
Weitere Artikel
Format: Online-Artikel
Genre: Key words Immunotherapy, Monoclonal antibodies, Hodgkin's lymphoma
Sprache: English
Veröffentlicht: 2000
Beschreibung: Online-Ressource
Online Zugang: Online
Volltext
Tags: Hinzufügen
Keine Tags. Fügen Sie den ersten Tag hinzu!
Anmerkung: Copyright: Copyright 2000 Springer-Verlag Berlin Heidelberg
LEADER 03091nma a2200433 c 4500
001 NLEJ202863883
003 DE-601
005 20110128153518.0
007 cr uuu---uuuuu
008 070528s2000 000 0 eng d
016 7 |a 1458489x  |2 DE-600 
040 |b ger  |c GBVCP 
041 0 |a eng 
084 |a soj  |2 natliz 
245 0 0 |a Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Copyright: Copyright 2000 Springer-Verlag Berlin Heidelberg 
520 |a Abstract Fifteen patients with refractory Hodgkin's disease were treated in a dose-escalation trial with the bispecific monoclonal antibody (bi-mAb) HRS-3/A9, which is directed against the Fcγ receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen. Treatment consisted of four cycles of four bi-mAb infusions given over 1 h every 3–4 days at different dose levels ranging from 1 mg/m2 to 64 mg/m2. Measurable serum levels (above 0.1 μg/ml) of circulating bi-mAb could be detected in patients treated with doses above 4 mg/m2, reaching peak levels of 9.5 μg/ml immediately after the end of antibody infusion on the highest dose level. Bi-mAb elimination corresponded to second-order kinetics with a terminal half-life time (t 1/2,β) of 28–32 h. Bi-mAb treatment induced the occurrence of human anti-(mouse Ig) antibodies (HAMA) in 6 out of 13 patients initially testing negative. All 6 patients not only developed anti-isotypic anti-(mouse Ig) but also anti-idiotypic and anti-anti-idiotypic antibodies. While no consistent changes of peripheral blood cell counts, or of any lymphocyte subpopulation including natural killer (NK) cells, has been observed, 4 out of 6 evaluable patients treated with doses of at least 4 mg/m2 showed an increase of NK cell activity within 2 weeks after treatment, which lasted for a maximum of 12 weeks. Circulating amounts of soluble CD30 antigen could be detected in the serum of 6 patients. However, like the results and time courses of all the other immunological parameters evaluated, this was not predictive for treatment outcome. 
533 |a Online edition  |f Springer Online Journal Archives 1860-2002 ; 041039-1 
655 7 |a Key words Immunotherapy  |2 gnd 
655 7 |a Monoclonal antibodies  |2 gnd 
655 7 |a Hodgkin's lymphoma  |2 gnd 
689 0 0 |a Key words Immunotherapy 
689 0 1 |a Monoclonal antibodies 
689 0 2 |a Hodgkin's lymphoma 
689 0 |5 DE-601 
700 1 |a Renner, Christoph 
700 1 |a Hartmann, Frank 
700 1 |a Jung, Wolfram 
700 1 |a Deisting, Christina 
700 1 |a Juwana, Marieta 
700 1 |a Pfreundschuh, Michael 
773 0 8 |i in  |t Cancer immunology immunotherapy : CII  |g Vol. 49 (2000), p. 173-180  |q 49<173-180  |w (DE-601)NLEJ188986774  |x 1432-0851 
856 4 0 |u http://dx.doi.org/10.1007/s002620050617 
901 |a OLC 
912 |a ZDB-1-SOJ 
912 |a GBV_NL_ARTICLE 
951 |a AR 
952 |d 49  |j 2000  |c 3  |h 173-180  |g 8 

Ähnliche Einträge

Keine ähnlichen Titel gefunden

Privacy Notice Ask a Librarian New Acquisitions